<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489968</url>
  </required_header>
  <id_info>
    <org_study_id>1275.13</org_study_id>
    <nct_id>NCT02489968</nct_id>
  </id_info>
  <brief_title>Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase III, Randomised, Double-blind, Parallel Group, 24-week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and Linagliptin 5 mg Fixed Dose Combination Compared With Empagliflozin 10 mg Plus Placebo and a 52-week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 25 mg and Linagliptin 5 mg Fixed Dose Combination Compared With Empagliflozin 25 mg Plus Placebo in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16-week Treatment With Empagliflozin (10 mg or 25 mg) Alone Once Daily.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Two independent study parts (i.e. Part A and Part B) are included in this trial. Part A will
      evaluate empagliflozin 10 mg + linagliptin and Part B will evaluate empagliflozin 25 mg +
      linagliptin. All analyses will be carried out separately for these study parts. The objective
      of Part A is to investigate the efficacy, safety and tolerability of the fixed dose
      combination (FDC) of empagliflozin 10 mg / linagliptin 5 mg compared with empagliflozin 10 mg
      plus FDC matching placebo administered orally once daily for 24 weeks in Japanese patients
      with T2DM (Type 2 Diabetes Mellitus) who have insufficient glycaemic control after 16 weeks
      of treatment with empagliflozin 10 mg alone once daily. The study is designed to show
      superiority of the FDC of empagliflozin 10 mg / linagliptin 5 mg over empagliflozin 10 mg
      plus FDC matching placebo after 24 weeks of treatment. The objective of Part B is to
      investigate the efficacy, safety and tolerability of the FDC of empagliflozin 25 mg /
      linagliptin 5 mg compared with empagliflozin 25 mg plus FDC matching placebo administered
      orally once daily for 24 weeks in Japanese patients with T2DM who have insufficient glycaemic
      control after 16 weeks of treatment with empagliflozin 25 mg alone once daily. The study is
      designed to show superiority of the FDC of empagliflozin 25 mg / linagliptin 5 mg over
      empagliflozin 25 mg plus FDC matching placebo after 24 weeks of treatment. The 24 week
      treatment period will be followed by a 28 week extension treatment period to evaluate further
      efficacy and safety up to 52 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2015</start_date>
  <completion_date type="Actual">June 16, 2017</completion_date>
  <primary_completion_date type="Actual">November 18, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment</measure>
    <time_frame>Baseline and 24 week</time_frame>
    <description>Change from baseline in HbA1c (%) after 24 weeks of treatment with double-blind trial medication. Change was calculated as: HbA1c value at 24-week - HbA1c value at baseline, for each patient. Baseline was defined as the last observation before the first intake of double-blind randomised trial medication. Statistical analysis presented is based on a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach. Full Analysis Set (Observed Cases) [FAS (OC)]: This analysis set consisted of all patients who were randomised and treated with at least 1 dose of trial drug during the double-blind part of the trial and who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the 24-week double-blind part of the trial. Observed cases analysis included only the available data that were observed while patients were on treatment, i.e., excluding the missing data.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">880</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>empagliflozin 10 mg + linagliptin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a tablet containing low dose empagliflozin and linagliptin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a tablet containing low dose empagliflozin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin 25 mg + linagliptin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a tablet containing high dose empagliflozin and linagliptin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients to receive a tablet containing high dose empagliflozin once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin 10 mg + linagliptin 5 mg</intervention_name>
    <description>empagliflozin low dose + linagliptin once daily</description>
    <arm_group_label>empagliflozin 10 mg + linagliptin 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin 10 mg</intervention_name>
    <description>empagliflozin low dose once daily</description>
    <arm_group_label>empagliflozin 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin 25 mg + linagliptin 5 mg</intervention_name>
    <description>empagliflozin high dose + linagliptin once daily</description>
    <arm_group_label>empagliflozin 25 mg + linagliptin 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin 25 mg</intervention_name>
    <description>empagliflozin high dose once daily</description>
    <arm_group_label>empagliflozin 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>empagliflozin 10 mg</arm_group_label>
    <arm_group_label>empagliflozin 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of type 2 diabetes prior to informed consent

          -  Male and female patients on diet and exercise regimen for at least 12 weeks prior to
             informed consent who are:

               -  drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to
                  informed consent or,

               -  pre-treated with one oral antidiabetic drug (for sulfonylurea, with up to half of
                  the maximum approved dose) on stable dosage for at least 12 weeks prior to the
                  informed consent (for thiazolidinedione, therapy has to be unchanged for at least
                  18 weeks prior to the informed consent). Individual antidiabetic drug will have
                  to be discontinued at Visit 1.

          -  haemoglobin A1c (HbA1c) at Visit 1 (screening)

               -  for patients without antidiabetic therapy : HbA1c &gt;=8.0 to =&lt;10.5%

               -  for patients with one oral antidiabetic drug : HbA1c &gt;=7.5 to =&lt;10.5%

          -  HbA1c &gt;=7.5 to =&lt;10.0% at Visit 4 for randomisation into the double blind treatment
             period

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose level &gt;270 mg/dL (&gt;15.0 mmol/L) during the
             open label stabilisation period and placebo run in period

          -  Impaired renal function, defined as estimated glomerular filtration rate (eGFR) &lt;45
             mL/min/1.73m2 (modification of diet in renal disease (MDRD) formula)

          -  Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks
             prior to informed consent

          -  Indication of liver disease, defined by serum levels of either alanine transaminase
             (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper
             limit of normal (ULN)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tokai Memorial Hospital</name>
      <address>
        <city>Aichi, Kasugai</city>
        <zip>487-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Organization of Occupational Health and Safety Chubu Rosai Hospital</name>
      <address>
        <city>Aichi, Nagoya</city>
        <zip>455-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokuyama Clinic</name>
      <address>
        <city>Chiba, Chiba</city>
        <zip>261-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuyama Shimin Hospital</name>
      <address>
        <city>Ehime, Matsuyama</city>
        <zip>790-0067</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanaka Int. Clinic, Ehime, DIA Med.,CV Med.</name>
      <address>
        <city>Ehime, Niihama</city>
        <zip>792-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murakami Memorial Hp., Ehime, I.M.</name>
      <address>
        <city>Ehime, Saijo</city>
        <zip>793-0030</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kunisaki Makoto Clinic, Fukuoka, I.M./CV Med.</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <zip>819-0168</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Shin Mizumaki Hospital</name>
      <address>
        <city>Fukuoka, Onga</city>
        <zip>807-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Yukuhashi Hospital</name>
      <address>
        <city>Fukuoka, Yukuhashi</city>
        <zip>824-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hashimoto I.M., Gifu, I.M.</name>
      <address>
        <city>Gifu, Gifu</city>
        <zip>500-8225</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kikuchi Naika Clinic, Gunma, I.M.</name>
      <address>
        <city>Gunma, Maebashi</city>
        <zip>370-3573</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hasegawa Internal Medicine Clinic</name>
      <address>
        <city>Hokkaido, Chitose</city>
        <zip>066-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ebetsu Internal Medicine Clinic</name>
      <address>
        <city>Hokkaido, Ebetsu</city>
        <zip>067-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hakodate Koseiin Hakodate Central General Hospital</name>
      <address>
        <city>Hokkaido, Hakodate</city>
        <zip>040-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iida Medical Clinic</name>
      <address>
        <city>Hokkaido, Hakodate</city>
        <zip>042-0942</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurihara Clinic</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <zip>004-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uehara Clinic</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <zip>006-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manda Memorial Hospital</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <zip>060-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Diabetes, Thyroid Clinic</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <zip>060-0807</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Community Health Care Organization Hokkaido Hospital</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <zip>062-8618</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashiya Municipal Hospital</name>
      <address>
        <city>Hyogo, Ashiya</city>
        <zip>659-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Itabashi DIA Med. and DERM Clinic, Ibaraki, I.M.</name>
      <address>
        <city>Ibaraki, Koga</city>
        <zip>306-0232</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Namegata District General Hospital</name>
      <address>
        <city>Ibaraki, Namegata</city>
        <zip>311-3516</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokuriku Hp., Ishikawa, I.M.</name>
      <address>
        <city>Ishikawa, Kanazawa</city>
        <zip>921-8035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oikawa Clinic</name>
      <address>
        <city>Iwate, Morioka</city>
        <zip>020-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirano Medical Clinic</name>
      <address>
        <city>Iwate, Morioka</city>
        <zip>020-0132</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwamoto Clinic, Kagawa, DIAB I.M.</name>
      <address>
        <city>Kagawa, Zentsuji</city>
        <zip>765-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenpozan Clinic of I.M., Kagoshima, I.M.</name>
      <address>
        <city>Kagoshima, Kagoshima</city>
        <zip>890-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hayashi DIA Clinic, Kanagawa, DIA Tract Med.·I.M.</name>
      <address>
        <city>Kanagawa, Chigasaki</city>
        <zip>253-0044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takai Naika Clinic</name>
      <address>
        <city>Kanagawa, Kamakura</city>
        <zip>247-0056</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagatsuta Family Clinic, Kanagawa, I.M.</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <zip>226-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Motomachi Takatsuka Naika Clinic, Kanagawa, I.M.</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <zip>231-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Minoru Clinic</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <zip>232-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morinagaueno clinic, Kumamoto, Digestive Tract I.M.</name>
      <address>
        <city>Kumamoto, Kumamoto</city>
        <zip>860-0863</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto, Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinnouchi Clinic Diabetes Care Center</name>
      <address>
        <city>Kumamoto, Kumamoto</city>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kajiyama Clinic, Kyoto, I.M.</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <zip>615-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsumoto Nakagawa Hospital</name>
      <address>
        <city>Nagano, Matsumoto</city>
        <zip>399-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ota DIA I.M. Clinic, Nagano, I.M.</name>
      <address>
        <city>Nagano, Nagano</city>
        <zip>380-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Niigata Daini Hp., Niigata, METAB ENDO</name>
      <address>
        <city>Niigata, Niigata</city>
        <zip>950-1104</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsuyama Chuo Hospital</name>
      <address>
        <city>Okayama, Tsuyama</city>
        <zip>708-0841</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaesu Clinic, Okinawa, I.M.</name>
      <address>
        <city>Okinawa, Naha</city>
        <zip>900-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanaka Clinic, Okinawa, I.M.</name>
      <address>
        <city>Okinawa, Tomigusuku</city>
        <zip>901-0244</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umeda Oak Clinic, Osaka, I.M.</name>
      <address>
        <city>Osaka, Osaka</city>
        <zip>530-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinugawa CARDIOL Clinic, Osaka, I.M.</name>
      <address>
        <city>Osaka, Osaka</city>
        <zip>532-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikeoka Clinic, Osaka, I.M.</name>
      <address>
        <city>Osaka, Osaka</city>
        <zip>536-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanko Clinic, Osaka, I.M.</name>
      <address>
        <city>Osaka, Osaka</city>
        <zip>559-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OCROM Clinic</name>
      <address>
        <city>Osaka, Suita</city>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC Nishi-umeda Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiraiwa Medical Clinic, Osaka, I.M.</name>
      <address>
        <city>Osaka</city>
        <zip>582-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saga Memorial Hospital</name>
      <address>
        <city>Saga, Saga</city>
        <zip>849-0917</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odayaka Life Naika Clinic, Saitama, I.M.</name>
      <address>
        <city>Saitama, Koshigaya</city>
        <zip>343-0828</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical corporation Chisei-kai Watanabe clinic</name>
      <address>
        <city>Saitama, Okegawa</city>
        <zip>363-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Toujinkai Sakado Central Hospital</name>
      <address>
        <city>Saitama, Sakado</city>
        <zip>350-0233</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAINO Clinic,</name>
      <address>
        <city>Saitama, Tokorozawa</city>
        <zip>359-1141</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamamatsu Rosai Hospital</name>
      <address>
        <city>Shizuoka, Hamamatsu</city>
        <zip>430-8525</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plumeria Clinic, Shizuoka, I.M.</name>
      <address>
        <city>Shizuoka, Shizuoka</city>
        <zip>422-8006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakakusa Clinic, Tochigi, I.M.</name>
      <address>
        <city>Tochigi, Shimotsuke</city>
        <zip>329-0433</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihonbashi Sakura Clinic</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <zip>103-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuwa Clinic</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihonbashi Enomoto Internal Medicine</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo-Eki Center-building Clinic</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Center Clinic</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosono Clinic</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <zip>104-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AGE Makita Medical Clinic</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <zip>104-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasai Diabetes Clinic</name>
      <address>
        <city>Tokyo, Edogawa-ku</city>
        <zip>134-0084</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Medical Research System Clinic</name>
      <address>
        <city>Tokyo, Hachioji</city>
        <zip>192-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Keikokai P1-Clinic</name>
      <address>
        <city>Tokyo, Hachioji</city>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minamino Heart Clinic</name>
      <address>
        <city>Tokyo, Hachioji</city>
        <zip>192-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinkoiwa Ekimae Sougou Clinic</name>
      <address>
        <city>Tokyo, Katushika-ku</city>
        <zip>124-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musashino Polyclinic</name>
      <address>
        <city>Tokyo, Kiyose</city>
        <zip>204-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pedi Shiodome Clinic</name>
      <address>
        <city>Tokyo, Minato-ku</city>
        <zip>105-7390</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinagawa East one Medical Clinic</name>
      <address>
        <city>Tokyo, Minato-ku</city>
        <zip>108-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimamura Kinen Hospital</name>
      <address>
        <city>Tokyo, Nerima-ku</city>
        <zip>177-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenkoukan Suzuki Clinic</name>
      <address>
        <city>Tokyo, Ota-ku</city>
        <zip>143-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Honda Hidehiko Clinic</name>
      <address>
        <city>Tokyo, Ota-ku</city>
        <zip>143-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakayori Clinic</name>
      <address>
        <city>Tokyo, Shinagawa-ku</city>
        <zip>140-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miho Clinic</name>
      <address>
        <city>Tokyo, Shinagawa-ku</city>
        <zip>141-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ToCROM Clinic</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <zip>160-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikebukuro Metropolitan Clinic</name>
      <address>
        <city>Tokyo, Toshima-ku</city>
        <zip>171-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanda Clinic, Tokyo, I.M.</name>
      <address>
        <city>Tokyo</city>
        <zip>101-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujikoshi Hp., Toyama, I.M.</name>
      <address>
        <city>Toyama, Toyama</city>
        <zip>930-0964</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Sugiyama, Yamagata, I.M.</name>
      <address>
        <city>Yamagata, Yamagata</city>
        <zip>990-0885</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Synopsis Link</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <results_first_submitted>November 16, 2017</results_first_submitted>
  <results_first_submitted_qc>September 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2018</results_first_posted>
  <last_update_submitted>September 3, 2018</last_update_submitted>
  <last_update_submitted_qc>September 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>880 subjects started the open label period</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Empagliflozin 10 mg OL</title>
          <description>Patients were administered empagliflozin 10 milligram (mg) tablets, orally with water, once daily for 16-weeks of open-label stabilisation period.</description>
        </group>
        <group group_id="P2">
          <title>Empagliflozin 25 mg OL</title>
          <description>Patients were administered empagliflozin 25 mg tablets, orally with water, once daily for 16-weeks of open-label stabilisation period.</description>
        </group>
        <group group_id="P3">
          <title>Empagliflozin 10 mg + Linagliptin 5 mg</title>
          <description>Patients who received empagliflozin 10 mg during open-label stabilisation period were randomized to receive a fixed dose combination (FDC) tablet of empagliflozin 10 mg and linagliptin 5 mg along with a matching placebo of empagliflozin 10 mg, orally with water, once daily for 24-weeks of double-blind treatment period.</description>
        </group>
        <group group_id="P4">
          <title>Empagliflozin 10 mg + Placebo</title>
          <description>Patients who received empagliflozin 10 mg during open-label stabilisation period were randomized to receive empagliflozin 10 mg along with a matching placebo of the FDC tablet of empagliflozin 10 mg and linagliptin 5 mg, orally with water, once daily for 24-weeks of double-blind treatment period.</description>
        </group>
        <group group_id="P5">
          <title>Empagliflozin 25 mg + Linagliptin 5 mg</title>
          <description>Patients who received empagliflozin 25 mg during open-label stabilisation period were randomized to receive a FDC tablet of empagliflozin 25 mg and linagliptin 5 mg along with a matching placebo of empagliflozin 25 mg, orally with water, once daily for 52-weeks of double-blind treatment period.</description>
        </group>
        <group group_id="P6">
          <title>Empagliflozin 25 mg + Placebo</title>
          <description>Patients who received empagliflozin 25 mg during open-label stabilisation period were randomized to receive empagliflozin 25 mg along with a matching placebo of the FDC tablet of empagliflozin 25 mg and linagliptin 5 mg, orally with water, once daily for 52-weeks of double-blind treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-label Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="439"/>
                <participants group_id="P2" count="440">1 subject did not receive treatment and hence excluded. Started represents treated numbers.</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
                <participants group_id="P2" count="232"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="208"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified above</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="189"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="107"/>
                <participants group_id="P4" count="108"/>
                <participants group_id="P5" count="116"/>
                <participants group_id="P6" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="105"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="110"/>
                <participants group_id="P6" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Open-label full analysis set (OLFAS) consisted of all patients in the open-label period who received at least 1 dose of open-label study drug during the trial and had a pre-treatment Glycated haemoglobin A1c (HbA1c) assessment and at least 1 on-treatment HbA1c assessment during the open-label part of the trial.</population>
      <group_list>
        <group group_id="B1">
          <title>Empagliflozin 10 mg OL</title>
          <description>Patients were administered empagliflozin 10 milligram (mg) tablets, orally with water, once daily for 16-weeks of open-label stabilisation period.</description>
        </group>
        <group group_id="B2">
          <title>Empagliflozin 25 mg OL</title>
          <description>Patients were administered empagliflozin 25 mg tablets, orally with water, once daily for 16-weeks of open-label stabilisation period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="435"/>
            <count group_id="B2" value="433"/>
            <count group_id="B3" value="868"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="10.2"/>
                    <measurement group_id="B2" value="57.5" spread="10.0"/>
                    <measurement group_id="B3" value="57.2" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="235"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="324"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment</title>
        <description>Change from baseline in HbA1c (%) after 24 weeks of treatment with double-blind trial medication. Change was calculated as: HbA1c value at 24-week - HbA1c value at baseline, for each patient. Baseline was defined as the last observation before the first intake of double-blind randomised trial medication. Statistical analysis presented is based on a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach. Full Analysis Set (Observed Cases) [FAS (OC)]: This analysis set consisted of all patients who were randomised and treated with at least 1 dose of trial drug during the double-blind part of the trial and who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the 24-week double-blind part of the trial. Observed cases analysis included only the available data that were observed while patients were on treatment, i.e., excluding the missing data.</description>
        <time_frame>Baseline and 24 week</time_frame>
        <population>FAS (OC)</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 10 mg + Linagliptin 5 mg</title>
            <description>Patients who received empagliflozin 10 mg during open-label stabilisation period were randomized to receive a fixed dose combination (FDC) tablet of empagliflozin 10 mg and linagliptin 5 mg along with a matching placebo of empagliflozin 10 mg, orally with water, once daily for 24-weeks of double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg + Placebo</title>
            <description>Patients who received empagliflozin 10 mg during open-label stabilisation period were randomized to receive empagliflozin 10 mg along with a matching placebo of the FDC tablet of empagliflozin 10 mg and linagliptin 5 mg, orally with water, once daily for 24-weeks of double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg + Linagliptin 5 mg</title>
            <description>Patients who received empagliflozin 25 mg during open-label stabilisation period were randomized to receive a FDC tablet of empagliflozin 25 mg and linagliptin 5 mg along with a matching placebo of empagliflozin 25 mg, orally with water, once daily for 52-weeks of double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg + Placebo</title>
            <description>Patients who received empagliflozin 25 mg during open-label stabilisation period were randomized to receive empagliflozin 25 mg along with a matching placebo of the FDC tablet of empagliflozin 25 mg and linagliptin 5 mg, orally with water, once daily for 52-weeks of double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment</title>
          <description>Change from baseline in HbA1c (%) after 24 weeks of treatment with double-blind trial medication. Change was calculated as: HbA1c value at 24-week - HbA1c value at baseline, for each patient. Baseline was defined as the last observation before the first intake of double-blind randomised trial medication. Statistical analysis presented is based on a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach. Full Analysis Set (Observed Cases) [FAS (OC)]: This analysis set consisted of all patients who were randomised and treated with at least 1 dose of trial drug during the double-blind part of the trial and who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the 24-week double-blind part of the trial. Observed cases analysis included only the available data that were observed while patients were on treatment, i.e., excluding the missing data.</description>
          <population>FAS (OC)</population>
          <units>Percentage (%)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="0.05"/>
                    <measurement group_id="O2" value="-0.12" spread="0.06"/>
                    <measurement group_id="O3" value="-0.91" spread="0.05"/>
                    <measurement group_id="O4" value="-0.33" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>REML based MMRM</method>
            <method_desc>Model including baseline HbA1c, treatment, baseline renal function, prior use of antidiabetic drug, visit, and visit by treatment interaction.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>-0.67</ci_upper_limit>
            <estimate_desc>Adjusted mean difference: Change in HbA1c in (empagliflozin 10 mg + linagliptin 5 mg) - change in HbA1c in (empagliflozin 10 mg + placebo)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>REML based MMRM</method>
            <method_desc>Model including baseline HbA1c, treatment, baseline renal function, prior use of antidiabetic drug, visit, and visit by treatment interaction.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>-0.45</ci_upper_limit>
            <estimate_desc>Adjusted mean difference: Change in HbA1c in (empagliflozin 25 mg + linagliptin 5 mg) - change in HbA1c in (empagliflozin 25 mg + placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration till two weeks after last drug administration; up to 72 weeks (including 16 weeks open-label, 2 weeks run-in period and 52 weeks double-blind treatment period).</time_frame>
      <desc>All patients who were randomised and treated with at least 1 dose of trial drug during open-label and double-blind part of the trial. Adverse events were coded using the MedDRA coding system version 19.1 (Week 24 analysis) and version 20.0 (Week 52 analysis).</desc>
      <group_list>
        <group group_id="E1">
          <title>Empagliflozin 25 mg + Linagliptin 5 mg</title>
          <description>Patients who received empagliflozin 25 mg during open-label stabilisation period were randomized to receive a FDC tablet of empagliflozin 25 mg and linagliptin 5 mg along with a matching placebo of empagliflozin 25 mg, orally with water, once daily for 52-weeks of double-blind treatment period.</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin 10 mg + Linagliptin 5 mg</title>
          <description>Patients who received empagliflozin 10 mg during open-label stabilisation period were randomized to receive a fixed dose combination (FDC) tablet of empagliflozin 10 mg and linagliptin 5 mg along with a matching placebo of empagliflozin 10 mg, orally with water, once daily for 24-weeks of double-blind treatment period.</description>
        </group>
        <group group_id="E3">
          <title>Empagliflozin 25 mg + Placebo</title>
          <description>Patients who received empagliflozin 25 mg during open-label stabilisation period were randomized to receive empagliflozin 25 mg along with a matching placebo of the FDC tablet of empagliflozin 25 mg and linagliptin 5 mg, orally with water, once daily for 52-weeks of double-blind treatment period.</description>
        </group>
        <group group_id="E4">
          <title>Empagliflozin 10 mg + Placebo</title>
          <description>Patients who received empagliflozin 10 mg during open-label stabilisation period were randomized to receive empagliflozin 10 mg along with a matching placebo of the FDC tablet of empagliflozin 10 mg and linagliptin 5 mg, orally with water, once daily for 24-weeks of double-blind treatment period.</description>
        </group>
        <group group_id="E5">
          <title>Empagliflozin 25 mg OL</title>
          <description>Patients were administered empagliflozin 25 mg tablets, orally with water, once daily for 16-weeks of open-label stabilisation period.</description>
        </group>
        <group group_id="E6">
          <title>Empagliflozin 10 mg OL</title>
          <description>Patients were administered empagliflozin 10 milligram (mg) tablets, orally with water, once daily for 16-weeks of open-label stabilisation period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Torus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Lymphangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Lateral medullary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Mediastinal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="131" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="120" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="47" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood ketone body increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="440"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="439"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

